Results 101 to 110 of about 6,373 (223)

SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights. [PDF]

Int J Mol Sci
Saraceno E, Serra I, Bracci B, Pagliardini V, Pinon M, Tuli G, Versace A, Bondone C, Spada M.   +8 more
europepmc   +1 more source

Pediatric Hepatology: A three-year experience with pediatric liver transplantation with cyclosporine and steroids [PDF]

, 1986
Gartner, JC, Iwatsuki, S, Malatack, JJ, Shaw, BW, Starzl, TE, Urbach, AH, Zitelli, BH   +6 more
core  

Different Clinic, Different Diagnosis: Tyrosinemia Type 3. [PDF]

Mol Syndromol
Basan H, Ceylaner S, Küçükcongar Yavaş A.   +2 more
europepmc   +1 more source

Pediatric liver transplantation with cyclosporine and steroids [PDF]

, 1984
Gartner, JC, Iwatsuki, S, Malatack, JJ, Shaw, BW, Starzl, TE, Urbach, AH, Zitelli, BJ   +6 more
core  

Untargeted Metabolomics Reveals Metabolic Reprogramming Linked to HCC Risk in Late Diagnosed Tyrosinemia Type 1. [PDF]

Metabolites
Sidorina A, Rizzo C, Leal-Witt MJ, Arias C, Cortés I, Cornejo V, Sacchetti E, Catesini G, Boenzi S, Dionisi-Vici C, Fuenzalida K.   +10 more
europepmc   +1 more source

Opportunities and costs of clinical research. [PDF]

, 1985
Gavaler, JS, Starzl, TE, Tarter, R, Van Thiel, DH   +3 more
core   +1 more source

Perioperative management of pediatric patients with inborn errors of metabolism during liver transplantation. [PDF]

World J Transplant
Paulin S, Rajakumar A, Menon J, Shanmugam N, Rela M.   +4 more
europepmc   +1 more source

Liver homotransplantation [PDF]

, 1986
Iwatsuki, S, Shaw, BW, Starzl, TE
core  

Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria. [PDF]

Ann Med Surg (Lond)
Chandani HK, Hujjat SFZ, Chandani DK, Khan MS, Mahmoud A.   +4 more
europepmc   +1 more source

[Tyrosinemia].

Revista chilena de pediatria, 1981
E, Saelzer, C, Norero, T, Young
openaire   +1 more source